DaVita (DVA) Earnings Date & Reports

Key Takeaways

• DaVita reported third-quarter 2026 revenue of approximately $3.58 billion, up about 4.6% year over year and slightly ahead of consensus estimates.
• Adjusted diluted earnings per share (EPS) came in at $3.82, beating analyst expectations, while GAAP (Generally Accepted Accounting Principles) EPS of $3.40 reflected one-time charges.
• The company kept its full-year 2026 adjusted diluted EPS guidance at $14.30 to $15.20, a midpoint below some consensus views.
• Operating cash flow and free cash flow both declined sharply year over year, drawing investor attention.
• U.S. dialysis treatment volumes grew modestly, with normalized non-acquired treatment growth of 0.4%.
• For more information on DaVita's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Discover AI-driven trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

DaVita is one of the largest kidney care and dialysis providers in the United States, and its quarterly results offer a direct read on treatment volumes, reimbursement trends, and cost pressures across the broader outpatient healthcare sector. The company generates most of its revenue from per-treatment reimbursement under government programs such as Medicare and Medicaid, along with commercial insurance plans. As a result, investors closely track how payor mix, treatment growth, and patient care costs translate into profitability. Coming into the quarter, DaVita had beaten consensus EPS estimates in each of its prior four reports, raising the bar for this release and making guidance, cash flow, and margin trends just as important as the headline numbers.

Reported Results

For the third quarter ended September 30, 2026, DaVita posted consolidated revenue of approximately $3.58 billion, up roughly 4.6% from the prior-year period and above consensus estimates near $3.52 billion. Adjusted diluted EPS reached $3.82, surpassing analyst expectations of roughly $3.55 to $3.78. On a GAAP basis, diluted EPS was $3.40, reflecting a $62 million non-cash goodwill and other asset impairment charge related to the company's China business.

Operating metrics showed modest momentum. U.S. dialysis treatments totaled about 7.33 million for the quarter, with normalized non-acquired treatment growth of 0.4% year over year. Revenue per treatment rose to $415.25 from $405.15 a year earlier, while patient care costs per treatment increased to $280.22 from $271.23, driven partly by higher compensation and supply costs.

On the cash flow side, operating cash flow declined to $519 million from $842 million a year ago, and free cash flow fell to $276 million from $604 million. Management maintained its full-year adjusted diluted EPS guidance of $14.30 to $15.20, with a midpoint of $14.75 that landed slightly below some consensus estimates. The company also repurchased 0.6 million shares for about $111 million during the quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking healthcare names like DaVita, it offers a faster way to surface candidates and compare signals across the sector.

Market Reaction and Investor Sentiment

Despite the top- and bottom-line beats, DaVita shares declined in after-hours trading following the release, as the market focused on guidance and cash flow rather than the headline results. The unchanged full-year EPS range, with a midpoint slightly below consensus, appeared to disappoint investors who had hoped for a more meaningful raise. Declining operating and free cash flow, along with the China-related impairment charge, added to the cautious tone. The reaction underscores that, for DaVita, quality of earnings and forward visibility often matter more than a single quarter's surprise. Sentiment heading into the report had been broadly positive, given the stock's strong year-to-date performance, which may have raised expectations and amplified the post-earnings pullback.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether DaVita can translate modest treatment volume growth into stronger free cash flow. Patient care costs per treatment have been rising, and any further pressure on wages, supplies, or insurance-related expenses could weigh on margins even as revenue per treatment trends higher.

Reimbursement dynamics remain a central theme. DaVita's results depend heavily on Medicare, Medicaid, and commercial payor rates, so any shifts in payor mix or government policy could influence profitability. Management's decision to keep full-year guidance unchanged suggests a balanced view, with cost discipline and volume trends offsetting reimbursement uncertainty.

The China business and its related impairment charge also warrant continued attention, as international operations introduce additional volatility. Finally, share repurchases and capital allocation will remain a focal point, since buybacks have historically supported EPS growth. For now, the key questions center on cash flow recovery, treatment growth sustainability, and whether management can lift its outlook in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations